eramkafusp alfa (IGN002)
/ Assertio
- LARVOL DELTA
Home
Next
Prev
1 to 9
Of
9
Go to page
1
February 08, 2021
[VIRTUAL] IGN002 (antiCD20-IFNα2b) intravenously administered tumor targeted delivery of IFNα2b and its effects in Non-Hodgkin Lymphoma
(TAT 2021)
- "Conclusions IGN002 demonstrated adequate stability in the tumor resulting in the reduction in tumor mass and increased survival when compared to rituximab. Thus, demonstrating that the targeted delivery of IFNα2b to CD20+ tumor warrants further investigation in NHL patients."
Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
November 05, 2020
[VIRTUAL] A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma
(ASH 2020)
- P1 | "The mAb portion of IGN002 is a chimeric IgG1 antibody with the same amino acid sequence as rituximab. Target Accrual:In the Dose-Escalation Stage and Expansion Stage, approximately 9-18 (~3-6 subjects per cohort) and 14 subjects, respectively, will be accrued. Enrollment for Cohort 6 is expected to commence in September 2020."
Clinical • P1 data • PK/PD data • Hematological Malignancies • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
March 11, 2022
A Study of IGN002 for Refractory NHL
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Spectrum Pharmaceuticals, Inc | N=62 ➔ 0 | Not yet recruiting ➔ Withdrawn
Enrollment change • Trial withdrawal • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology
March 11, 2022
Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
(clinicaltrials.gov)
- P1 | N=62 | Terminated | Sponsor: Spectrum Pharmaceuticals, Inc | Recruiting ➔ Terminated; Strategic Reasons
Trial termination • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20
April 19, 2021
Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
(clinicaltrials.gov)
- P1; N=62; Recruiting; Sponsor: Spectrum Pharmaceuticals, Inc; Suspended ➔ Recruiting
Enrollment open • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20
February 08, 2021
[VIRTUAL] IGN002 (antiCD20-IFNα2b) intravenously administered tumor targeted delivery of IFNα2b and its effects in Non-Hodgkin Lymphoma
(TAT 2021)
- "Importantly, the most frequently mutated genes in metastatic tumors were TP53 (100% of cases) and PTPRT (75% of cases). Conclusions Taken together, our findings indicate that metastatic LUSC associated with isolated BCH shows a highly mutable phenotype."
Hematological Malignancies • Lung Cancer • Lymphoma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor • Squamous Cell Carcinoma • MMP1 • MMP2 • RB1 • TP53
February 23, 2021
Spectrum Pharmaceuticals Announces Two Presentations at Upcoming ESMO TAT Virtual Congress 2021
(Businesswire)
- “Spectrum Pharmaceuticals…announced two presentations, one oral and one eposter, at the upcoming European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress 2021. The oral presentation will provide some initial safety and efficacy data for poziotinib from the twice daily dosing cohort. The meeting takes place on March 1 – 2, 2021…Title: IGN002 (antiCD20-IFNα2b) intravenously administered tumor targeted delivery of IFNα2b and its effects in non-Hodgkin lymphoma…Presentation Number: #20P (poster) Title: Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer”
Clinical data • Hematological Malignancies • Lung Cancer • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology
January 09, 2020
Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects
(clinicaltrials.gov)
- P1; N=62; Suspended; Sponsor: Spectrum Pharmaceuticals, Inc; Trial completion date: Dec 2018 ➔ Jan 2025; Recruiting ➔ Suspended; Trial primary completion date: Oct 2018 ➔ Nov 2024
Clinical • Trial completion date • Trial primary completion date • Trial suspension
January 09, 2020
A Study of IGN002 for Refractory NHL
(clinicaltrials.gov)
- P1; N=62; Not yet recruiting; Sponsor: Spectrum Pharmaceuticals, Inc; Phase classification: P2 ➔ P1; Trial completion date: Dec 2019 ➔ Dec 2025; Trial primary completion date: Dec 2019 ➔ Jul 2025
Clinical • Phase classification • Trial completion date • Trial primary completion date
1 to 9
Of
9
Go to page
1